Spots Global Cancer Trial Database for hsct
Every month we try and update this database with for hsct cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Granulocyte Transfusions After Umbilical Cord Blood Transplant | NCT05425043 | Pediatric Cance... | Granulocytes | - 16 Years | University of Manchester | |
| Safety and Efficacy of ThisCART19A Bridging Hematopoietic Stem Cell Transplantation in Patients With Refractory or Relapsed B-cell Acute Lymphoblastic Leukemia | NCT05576181 | Allogeneic, CAR... | ThisCART19A Fludarabine Ora... Cyclophosphamid... VP-16 HSCT | 14 Years - 75 Years | Fundamenta Therapeutics, Ltd. | |
| Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies | NCT01341301 | Hematologic Mal... | Total Body Irra... Donor Lymphocyt... Cyclophosphamid... Tacrolimus Mycophenolate m... Allogeneic hema... Laboratory biom... | 18 Years - | Thomas Jefferson University | |
| A Study of Olverembatinib Combined With Inotuzumab Ozogamicin in the Treatment ph+ ALL With MRD Persistent Positive | NCT05603156 | Ph+ ALL Bone Marrow Tra... Minimal Residua... | the usage of Ol... | 18 Years - | Institute of Hematology & Blood Diseases Hospital, China | |
| a Clinical Research of Sequential CAR-T Bridging HSCT in the Treatment of Relapse/Refractory B-cell Malignancies | NCT02846584 | Lymphoma, Large... Leukemia, Lymph... Lymphoma，Malign... | CD19 or CD20 CA... | 14 Years - 75 Years | Southwest Hospital, China | |
| A Research Study of Bone Marrow Transplantation From Unrelated or Partially Matched Related Donors | NCT01349101 | Hematological M... | Total Body Irra... Cyclophosphamid... Tacrolimus Mycophenolate m... Fludarabine Busulfan Hematopoietic s... | 18 Years - | Thomas Jefferson University | |
| Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors | NCT01608152 | Leukemia Lymphoma | Focus Group Internet-Based ... Interview | 15 Years - 39 Years | M.D. Anderson Cancer Center | |
| Patient Reported Outcomes and Patient Education in Cellular Therapy Patients | NCT04853277 | Stem Cell Trans... CAR T-Cell Tran... CAR T-Cell Ther... Cellular Therap... Hematopoietic S... HSCT Multiple Myelom... Leukemia Lymphoma | Education | 18 Years - | Dartmouth-Hitchcock Medical Center | |
| Study of Iomab-B vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid Leukemia | NCT02665065 | Acute Myeloid L... Leukemia, Acute... Myeloid Leukemi... Leukemia, Myelo... Acute Myelogeno... Leukemia, Acute... Myelogenous Leu... AML Bone Marrow Tra... | Iomab-B Conventional Ca... HCT | 55 Years - | Actinium Pharmaceuticals | |
| Safety and Efficacy of ThisCART19A Bridging Hematopoietic Stem Cell Transplantation in Patients With Refractory or Relapsed B-cell Acute Lymphoblastic Leukemia | NCT05576181 | Allogeneic, CAR... | ThisCART19A Fludarabine Ora... Cyclophosphamid... VP-16 HSCT | 14 Years - 75 Years | Fundamenta Therapeutics, Ltd. | |
| Autologous Cytomegalovirus (CMV)-Specific Cytotoxic T Cells for Cytomegalovirus (CMV) Reactivation | NCT02210065 | Leukemia Lymphoma | Cytomegalovirus... | 18 Years - | M.D. Anderson Cancer Center | |
| Unrelated Donor Stem Cell Transplantation | NCT01364363 | Severe Aplastic... Paroxysmal Noct... Acute Myelogeno... Acute Lymphobla... Myelodysplastic... Myeloproliferat... Chronic Myeloge... Hodgkin's Lymph... Non-Hodgkin's L... Multiple Myelom... Chronic Lymphoc... Small Lymphocyt... Large Granulocy... | Allogeneic tran... | 18 Years - 69 Years | Scripps Health | |
| Granulocyte Transfusions After Umbilical Cord Blood Transplant | NCT05425043 | Pediatric Cance... | Granulocytes | - 16 Years | University of Manchester | |
| Decitabine, Venetoclax and Blinatumomab for Maintenance Following HSCT in Patients With Ph-Negative B-ALL | NCT06393985 | B-cell Acute Ly... | Decitabine, ven... | 18 Years - 65 Years | The First Affiliated Hospital of Soochow University | |
| Respiratory Syncytial Virus - RSV Protocol | NCT01502072 | Bone Marrow Tra... Infection in Ma... Respiratory Syn... Respiratory Syn... Cancer Acute Leukemia | Ribavirin Ribavirin | 18 Years - | M.D. Anderson Cancer Center | |
| A Research Study of Bone Marrow Transplantation From Unrelated or Partially Matched Related Donors | NCT01349101 | Hematological M... | Total Body Irra... Cyclophosphamid... Tacrolimus Mycophenolate m... Fludarabine Busulfan Hematopoietic s... | 18 Years - | Thomas Jefferson University | |
| CAV Regimen Bridging to HSCT for R/R AL | NCT05190549 | Acute Leukemia,... Acute Leukemia ... | CAV regimen bri... | 16 Years - 70 Years | The First Affiliated Hospital of Soochow University | |
| Haplo-SCT vs ASCT With or Without Decitabine in AML CR1 | NCT02059720 | Acute Myeloid L... | HSCT | 18 Years - | The First Affiliated Hospital of Soochow University | |
| Standard of Care +/- Midostaurin to Prevent Relapse Post Stem Cell Transplant in Patients With FLT3-ITD Mutated AML | NCT01883362 | Acute Myeloid L... | Midostaurin Standard of Car... | 18 Years - 70 Years | Novartis | |
| Observatory of the Prescription of Erythropoietin as Treatment of Anemia Induced by Chemotherapy or Allograft Conditioning Among the Patients With a Haematological Malignancy | NCT02860598 | Anemia Acute Myeloid L... | 18 Years - | Hospices Civils de Lyon | ||
| Haematopoietic Stem Cell Transplantation (HSCT) in Comparison to Conventional Consolidation Therapy for Patients With Acute Myeloid Leukemia (AML) (Intermediate Risk) </= 60y. After First CR | NCT01246752 | Leukemia, Myelo... | Human Stem Cell... Consolidation c... | 18 Years - 60 Years | University Hospital Carl Gustav Carus | |
| A Research Study of Bone Marrow Transplantation From Unrelated or Partially Matched Related Donors | NCT01349101 | Hematological M... | Total Body Irra... Cyclophosphamid... Tacrolimus Mycophenolate m... Fludarabine Busulfan Hematopoietic s... | 18 Years - | Thomas Jefferson University | |
| Safety and Efficacy of ThisCART19A Bridging Hematopoietic Stem Cell Transplantation in Patients With Refractory or Relapsed B-cell Acute Lymphoblastic Leukemia | NCT05576181 | Allogeneic, CAR... | ThisCART19A Fludarabine Ora... Cyclophosphamid... VP-16 HSCT | 14 Years - 75 Years | Fundamenta Therapeutics, Ltd. | |
| Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies | NCT01341301 | Hematologic Mal... | Total Body Irra... Donor Lymphocyt... Cyclophosphamid... Tacrolimus Mycophenolate m... Allogeneic hema... Laboratory biom... | 18 Years - | Thomas Jefferson University | |
| Treosulfan-Based Conditioning Regimen Before a Blood or Bone Marrow Transplant for the Treatment of Bone Marrow Failure Diseases (BMT CTN 1904) | NCT04965597 | Bone Marrow Fai... Congenital Ameg... Congenital Pure... Hereditary Side... Paroxysmal Noct... Shwachman-Diamo... Hematologic Neo... Hematologic Neo... Hematologic Neo... | Treosulfan Fludarabine Pho... Tacrolimus Methotrexate Lapine T-Lympho... Peripheral Bloo... Allogeneic Bone... Quality-of-Life... Echocardiograph... Multigated Acqu... Bone Marrow Bio... Bone Marrow Asp... Biospecimen Col... | 1 Year - 49 Years | Fred Hutchinson Cancer Center | |
| Open-Label Study Designed to Evaluate the Safety and Preliminary Efficacy of ApoCell for the Prevention of Acute GvHD | NCT00524784 | Graft Versus Ho... Hematological M... | ApoCell | 18 Years - 60 Years | Hadassah Medical Organization | |
| Allogeneic Stem Cell Transplantation in Children and Adolescents With Acute Lymphoblastic Leukaemia | NCT01423747 | Lymphoblastic L... | VP16 TBI VP16, ATG TBI Fludarabine, OK... VP16, ATG TBI | 3 Months - 18 Years | St. Anna Kinderkrebsforschung | |
| Oral Posaconazole Three Times Per Day vs Weekly High Dose Amphotericin B Lipid Complex (ABLC) | NCT00750737 | Invasive Fungal... Hematologic Mal... | Posaconazole ABLC | 18 Years - | M.D. Anderson Cancer Center | |
| HD-Idarubicin/Etoposide Intensified Conditioning Regimen Allo-HSCT for Adult ALL | NCT01873807 | Acute Lymphobla... | IDA TBI CTX VP-16 | 16 Years - 65 Years | Nanfang Hospital, Southern Medical University | |
| Granulocyte Transfusions After Umbilical Cord Blood Transplant | NCT05425043 | Pediatric Cance... | Granulocytes | - 16 Years | University of Manchester | |
| An Open, Single Center, Randomized Controlled Clinical Study of UCB (Cord Blood) in the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML) | NCT05577611 | UCB (Cord Blood... | Basic chemother... | - | Zhongnan Hospital | |
| An Open, Single Center, Randomized Controlled Clinical Study of UCB (Cord Blood) in the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML) | NCT05577611 | UCB (Cord Blood... | Basic chemother... | - | Zhongnan Hospital | |
| CAV Regimen Bridging to HSCT for R/R AL | NCT05190549 | Acute Leukemia,... Acute Leukemia ... | CAV regimen bri... | 16 Years - 70 Years | The First Affiliated Hospital of Soochow University | |
| Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies | NCT01341301 | Hematologic Mal... | Total Body Irra... Donor Lymphocyt... Cyclophosphamid... Tacrolimus Mycophenolate m... Allogeneic hema... Laboratory biom... | 18 Years - | Thomas Jefferson University | |
| ALL-SCT BFM International- HSCT in Children and Adolescents With ALL | NCT01423500 | Lymphoblastic L... | VP16 TBI VP16, ATG TBI Fludarabine, OK... VP16, ATG TBI | 3 Months - 18 Years | St. Anna Kinderkrebsforschung | |
| Allo SCT in Amyloidosis Non-interventional Study | NCT02257905 | AL Amyloidosis | 18 Years - 60 Years | European Society for Blood and Marrow Transplantation | ||
| Respiratory Syncytial Virus - RSV Protocol | NCT01502072 | Bone Marrow Tra... Infection in Ma... Respiratory Syn... Respiratory Syn... Cancer Acute Leukemia | Ribavirin Ribavirin | 18 Years - | M.D. Anderson Cancer Center | |
| Evaluate the Safety and Efficacy for Oral Mucositis Prevention of MIT-001 in Auto HSCT | NCT05493800 | Oral Mucositis Lymphoma Multiple Myelom... Hematologic Can... | MIT-001 normal saline | 19 Years - 70 Years | MitoImmune Therapeutics | |
| Respiratory Syncytial Virus - RSV Protocol | NCT01502072 | Bone Marrow Tra... Infection in Ma... Respiratory Syn... Respiratory Syn... Cancer Acute Leukemia | Ribavirin Ribavirin | 18 Years - | M.D. Anderson Cancer Center | |
| A Study Evaluating Intensive Chemotherapy With or Without Glasdegib or Azacitidine With or Without Glasdegib In Patients With Previously Untreated Acute Myeloid Leukemia | NCT03416179 | Leukemia, Myelo... | glasdegib daunorubicin + ... azacitidine Placebo Placebo glasdegib cytarabine HSCT | 18 Years - | Pfizer | |
| Infusion of Allogeneic CD19-Specific T Cells From Peripheral Blood | NCT01497184 | Leukemia Lymphoma | HSCT DLI | 1 Year - 65 Years | M.D. Anderson Cancer Center | |
| Administration of Donor MultiTAA-Specific T Cells for ALL | NCT02475707 | Leukemia, Lymph... | MultiTAA-specif... | - | Baylor College of Medicine | |
| Safety and Efficacy of ThisCART19A Bridging Hematopoietic Stem Cell Transplantation in Patients With Refractory or Relapsed B-cell Acute Lymphoblastic Leukemia | NCT05576181 | Allogeneic, CAR... | ThisCART19A Fludarabine Ora... Cyclophosphamid... VP-16 HSCT | 14 Years - 75 Years | Fundamenta Therapeutics, Ltd. | |
| Unrelated Donor Stem Cell Transplantation | NCT01364363 | Severe Aplastic... Paroxysmal Noct... Acute Myelogeno... Acute Lymphobla... Myelodysplastic... Myeloproliferat... Chronic Myeloge... Hodgkin's Lymph... Non-Hodgkin's L... Multiple Myelom... Chronic Lymphoc... Small Lymphocyt... Large Granulocy... | Allogeneic tran... | 18 Years - 69 Years | Scripps Health | |
| Cytomegalovirus (CMV) Reactivation in Allogeneic HSCT Recipient | NCT03806764 | Cytomegalovirus... Haematological ... Organ or Tissue... Immune Suppress... | Blood sampling | 18 Years - | Melbourne Health | |
| Observatory of the Prescription of Erythropoietin as Treatment of Anemia Induced by Chemotherapy or Allograft Conditioning Among the Patients With a Haematological Malignancy | NCT02860598 | Anemia Acute Myeloid L... | 18 Years - | Hospices Civils de Lyon | ||
| Efficacy and Safety of Azacitidine Combined With Interferon in the Treatment of Post-transplant Recurrence | NCT04078399 | HSCT Efficacy and Sa... | Azacitidine com... | 14 Years - | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
